Immatics’ PRAME gift keeps on giving
The company dribbles out more data on IMA203, and the numbers head in the right direction.
The company dribbles out more data on IMA203, and the numbers head in the right direction.
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.